Postpericardiotomy syndrome

Article written and reviewed by Dr Luca Moretti

The postpericardiotomy syndrome is an inflammatory response that appears after cardiac surgery involving the pericardium and, frequently, the pleura. Pleuritic pain, fever, friction rubs, and effusions are the main manifestations, in variable combinations. It belongs to the post-cardiac injury syndromes, but the operative setting introduces specific problems: blood collections, adhesions, infections, coagulation abnormalities, and the need to maintain antithrombotic therapies.

The presence of fluid after surgery does not itself establish the diagnosis. A postoperative effusion may result from the normal tissue response, bleeding, or fluid overload, without a clinically significant inflammatory syndrome. An early increase in C-reactive protein is also expected after surgery. Diagnosis therefore requires temporal and clinical interpretation, not simply counting findings that are common during convalescence.

Recognizing the syndrome serves to treat inflammation, limit recurrences, and promptly identify compressive collections. The care pathway must remain linked to the cardiac surgical team, because a mechanical or infectious complication can mimic the same presentation and require completely different interventions.

Surgical context, frequency, and predisposing factors

Opening the pericardium exposes serosal surfaces to manipulation, blood, and products of cellular injury. Valve surgery, coronary surgery, and aortic procedures may be followed by the syndrome, with variable frequency. The anatomical extent of the procedure alone does not predict which patient will develop a clinically relevant response. The presentation also depends on the individual response and the conditions of convalescence, as well as on the technical characteristics of the operation.

The epidemiological estimates differ considerably because some studies include mild episodes identified during scheduled follow-up, whereas others consider only cases requiring treatment, readmission, or drainage. The high incidences reported in historical series are not equivalent to the probability of a severe complication. The clinical syndrome must be distinguished from echocardiographic collections, which are far more common. This distinction is also essential when comparing results among centers or interpreting the benefit of a preventive strategy.

A younger age and some procedural characteristics, such as pleural opening or valve and aortic surgery compared with isolated bypass surgery in certain cohorts, have been associated with greater frequency. These associations are not consistent and are not diagnostic criteria. Neither their absence excludes the syndrome nor does their presence justify a diagnosis in a patient without evidence of inflammatory activity. Risk must be interpreted in the context of the population studied.

The usual latency is days or weeks, often with onset after an initial improvement. Very early manifestations require particular caution because fever, pain, and increased biomarkers may directly reflect the operation. A late presentation is also possible, but as the interval lengthens, the importance of searching for alternative causes increases. Discharge documentation and previous test results help establish whether this is a new process or persistence of a complication that never resolved.

Residual blood and abnormalities of drainage may contribute to the local response and formation of collections. It is not correct, however, to identify every hematoma with the syndrome: clots and bleeding create mechanical problems that may require evacuation or surgical revision. Anticoagulant therapy, when necessary, modifies hemorrhagic risk and management but does not demonstrate an immune-mediated origin of the fluid. Interpretation must separate predisposing factors, direct causes, and clinical consequences.

Perioperative prevention should be considered within an overall program. Hemostasis control, drain function, and recognition of collections belong to surgical management; pharmacological prophylaxis of inflammation addresses a different question. A procedure that reduces local accumulation may improve some outcomes without eliminating the possibility of serositis. Similarly, a drug that reduces the syndrome does not necessarily prevent bleeding, mechanical tamponade, or all forms of effusion observed in the postoperative period.

Pathogenesis and abnormalities of cardiac filling

The response to injury involves innate immune signals and possible recognition of cardiac antigens exposed during surgery. Local activation promotes cellular infiltration, vasodilation, and exudation. The immune-mediated hypothesis is supported by latency, recurrences, and response to anti-inflammatory treatment, but it does not identify a single mechanism demonstrated in every patient. The term syndrome therefore describes a coherent set of manifestations without implying that all cases share the same immunological profile.

Cardiac autoantibodies have been studied as possible indicators of the response to injury, but they have no routine role in diagnosis or monitoring. Positivity may reflect antigen exposure without demonstrating that the antibodies are the principal mediators of disease. In practice, symptoms, inflammatory course, and imaging are more useful. Using immunological tests not validated for this purpose risks assigning causal significance to findings that do not alter therapeutic decisions.

The pleural component may be as important as the pericardial component. Pleuritic pain, pleural collections, and ventilatory limitation contribute to dyspnea and reduced mobilization. After surgery, atelectasis, infection, and congestion can produce similar or concomitant manifestations. Serosal inflammation should therefore be assessed across the thorax as a whole. The amount of pericardial fluid is not a complete measure of symptom burden and does not necessarily explain respiratory difficulty by itself.

Postoperative adhesions alter the distribution of collections. Fluid may organize into posterior or lateral pockets, compressing a chamber without producing the classic circumferential effusion. Local pressure may be clinically relevant even when the total volume appears modest. An organized hematoma also behaves differently from a free exudate, both in terms of visualization and feasibility of percutaneous drainage. Pathophysiology must be reconstructed according to the actual anatomy.

Postoperative tamponade may evolve rapidly or present subacutely with fatigue, dyspnea, congestion, and reduced perfusion. Venous pressure, volume status, and ventricular function influence the presentation. Positive-pressure ventilation may worsen the reduction in venous return in a patient who is already compromised. An inflammatory collection and residual blood may coexist: distinguishing their contributions helps select the mode of decompression and anticipate the risk of reaccumulation.

Inflammatory constriction is possible when edema and organization of the pericardial layers limit filling. Some of these presentations may regress, whereas others progress to persistent fibrosis. If congestion and constrictive physiology remain after drainage, an effusive-constrictive component should be considered. Comparison with preoperative cardiac function is essential because heart failure, right ventricular dysfunction, or residual valvular disease can explain similar symptoms and require treatment different from pericardial therapy.

Manifestations, clinical criteria, and differential diagnosis

The pleuritic pain may appear after discharge and differ from wound pain by its relationship to breathing and position. Fever, malaise, and reduced walking capacity may accompany it. The patient may report worsening after a period of recovery, but this sequence is not specific. Friction rubs and pleural findings support suspicion when present; their absence does not exclude the syndrome, especially in patients taking analgesics or with difficult auscultatory windows.

The clinical timeline should be reconstructed with the date and type of surgery, intraoperative complications, drain characteristics, hemoglobin trend, and therapy at discharge. Temperature, biomarkers, and previous imaging should be compared. A collection already documented may enlarge for reasons other than inflammation, whereas a new fever may indicate infection. This reconstruction avoids labeling every problem that occurs in the month after surgery as postpericardiotomy syndrome, an error that can delay specific care.

The clinical criteria commonly used require at least two of the five elements listed below, in the appropriate temporal context and with evidence of inflammatory activity. In the early postoperative period, these findings have limited specificity. The numerical criterion helps make the diagnosis explicit but does not replace the distinction among normal recovery, infection, and hemorrhagic complication.

• Elements for clinical diagnosis
• Fever without another identified cause.
• Pain pericardial or pleuritic.
• Friction rub pericardial or pleural.
• Pericardial effusion.
• Pleural effusion with elevated C-reactive protein.

Postoperative infections include pneumonia, wound or mediastinal infection, bacteremia, and endocarditis involving operated or prosthetic structures. Chills, wound discharge, progressive local pain, instability, or persistent fever require targeted investigations. The simultaneous presence of an effusion does not make these conditions less likely. Before prescribing corticosteroids, infectious suspicion must be adequately addressed because improvement in fever could otherwise mask progressive disease.

The cardiopulmonary differential diagnosis includes ischemia, pulmonary embolism, ventricular dysfunction, arrhythmias, and valvular problems. Tachycardia may be a response to pain or a sign of low output; dyspnea may result from a pleural collection, anemia, or congestion. Examination includes perfusion, blood pressure, jugular veins, wound, and chest. Symptoms should be interpreted as a whole, avoiding the tendency to make an easily visible echocardiographic finding the automatic explanation for every abnormality.

Noninflammatory collections are particularly important because they may be asymptomatic and regress spontaneously. Their presence does not establish an indication for aspirin, NSAIDs, or colchicine. Conversely, hemorrhage or a compressive hematoma may require intervention even without fever or elevated C-reactive protein. The correct question is therefore twofold: determine whether an inflammatory syndrome exists and separately verify whether the pericardial contents compromise circulation or reflect an injury that is still active.

Imaging, laboratory testing, and subsequent investigations

The echocardiogram is the first examination for defining the collection, biventricular function, valvular apparatus, and signs of compression. It should describe distribution, not only maximum thickness. In the operated patient, air, dressings, and pain may limit acoustic windows; a technically incomplete assessment does not exclude a posterior collection. Comparison with previous imaging helps recognize significant changes and distinguish the new problem from dysfunction already known before symptom onset.

Transesophageal echocardiography can clarify hematomas and regional compression when transthoracic examination is insufficient. CT is useful for the anatomy of collections, mediastinum, pleura, and deep wound problems, according to the clinical question. The choice depends on stability and urgency. In hemodynamic deterioration with strong suspicion of a surgical complication, imaging should be organized together with cardiac surgical involvement, without becoming an obstacle to necessary decompression or revision.

Magnetic resonance imaging may be indicated in persistent or recurrent presentations to document pericardial activity and assess the reversibility of constriction. Edema and enhancement are interpreted together with symptoms and biomarkers. Residual positivity alone does not justify additional months of immunosuppression, whereas a collection with little inflammatory activity points toward other mechanisms. Compatibility of implanted materials and artifacts are assessed according to specific procedures; recent surgery does not automatically make every advanced examination impossible.

Serial laboratory testing includes complete blood count, C-reactive protein, renal function, and electrolytes; troponin and other tests follow the clinical suspicion. Falling hemoglobin may suggest bleeding but requires correlation with the entire course. Leukocytosis and C-reactive protein are nonspecific after surgery, so their trend is more informative than an isolated value. Blood cultures and microbiological investigations should be obtained when indicated, avoiding unverified attribution of fever to a sterile response.

The fluid analysis is selected when drainage is performed for clinical or diagnostic reasons. Bloody appearance, cellularity, and cultures may help, but no biochemical profile identifies the syndrome with certainty. A sample must be interpreted in relation to anticoagulation, time since surgery, and possible contamination. If infectious suspicion persists, a negative result after antibiotics does not have the same exclusion value as a sample obtained before treatment.

The subsequent definition of the disease includes first episode, persistent activity, or recurrence after remission; extent of pleural involvement; need for procedures; and any constriction. It should be determined whether the condition limits rehabilitation and whether correctable competing causes exist. Instability, a significant enlarging effusion, or mechanical uncertainty requires hospital care, whereas a stable form may be followed with a close monitoring plan. Access to follow-up and home circumstances contribute to the choice of level of care.

Treatment of the episode and recurrences

Anti-inflammatory therapy is directed at the active clinical syndrome. Aspirin or an NSAID is selected considering antiplatelet indication, bleeding risk, renal function, and comorbidities; gastroprotection accompanies regimens that require it. After coronary surgery, aspirin may be preferable when already indicated, but the antiplatelet dose and the anti-inflammatory dose are not equivalent. Tapering begins after control of symptoms and biological activity, avoiding discontinuation as soon as pain merely becomes tolerable.

Adjunctive colchicine may be added in inflammatory forms, with a regimen adjusted for weight, renal and hepatic function, and interactions. In adults, 0.5 mg once daily below 70 kg and 0.5 mg twice daily at 70 kg or above are commonly used, without a loading dose, when there is no reason to reduce or avoid the dose. The treatment duration for an episode is not the same as the one month used in preventive protocols: it generally follows the principles used for pericarditis, with at least three months for a first episode and longer periods for recurrences.

In this setting, corticosteroids are reserved for contraindications, intolerance, or inadequate control with initial options and for selected situations. Before their use, infectious risk should be reassessed. Dose and tapering should limit exposure and flares, especially when the patient is already frail or has diabetes and wound problems. A rapid response does not prove the diagnosis: many inflammatory causes improve transiently, whereas a compressive collection still requires mechanical assessment.

Pericardial drainage is required in tamponade and in other clinically relevant collections, with the method determined by location, contents, and accessibility. Free fluid may be reached percutaneously under imaging guidance; clots, loculations, and suspected active bleeding may favor a surgical approach. Treatment of serositis continues when indicated but does not replace evacuation. After decompression, persistent congestion requires investigation for constriction, ventricular dysfunction, or a valvular problem.

Antithrombotic management should be coordinated, considering prosthetic valves, atrial fibrillation, coronary interventions, and individual thrombotic risk. Automatically stopping necessary therapy may be dangerous; continuing it without reassessment in the presence of bleeding may be equally dangerous. NSAIDs and corticosteroids also modify the bleeding balance. The strategy should specify monitoring, any correction of coagulation, and timing of resumption if a procedure is required, keeping the antithrombotic decision separate from the label of inflammatory syndrome.

Difficult recurrences require confirmation of inflammatory activity, review of adherence, and reconsideration of alternative diagnoses. In selected recurrent inflammatory phenotypes, interleukin-1 blockade may be considered, taking into account the limited representation of different etiologies in trials. It is not a treatment intended for every post-sternotomy pain or residual effusion. Pericardiectomy is considered mainly for clinically significant persistent constriction, after defining reversibility, anatomy, and expected benefit in relation to the operated heart disease.

Prevention: evidence, applicability, and tolerability

Pharmacological prophylaxis must be distinguished from treatment of a syndrome that has already developed. The goal is to reduce clinical episodes after surgery, not necessarily to make every echocardiogram free of fluid. This distinction explains why positive studies on prevention of the syndrome can coexist with negative studies on treatment of postoperative collections. The decision considers expected risk, contraindications, and the ability to promptly recognize adverse effects during a phase already characterized by polypharmacy.

In the COPPS trial, colchicine started after surgery and continued for one month reduced the incidence of the syndrome compared with placebo. The result supports a preventive effect on postoperative inflammation but derives from specific criteria and patient selection. The historical protocol included administration methods that should not be reproduced without considering current recommendations and tolerability. Loading doses, in particular, are not required in common contemporary pericarditis treatment regimens.

The COPPS-2 trial studied perioperative initiation, from 48 to 72 hours before surgery, with continuation for one month. The syndrome occurred in 19.4% of patients assigned to colchicine and 29.4% of controls, an absolute difference of 10 percentage points. Adverse events were more frequent with colchicine, mainly because of gastrointestinal intolerance. The result quantifies both benefit and clinical cost, without justifying automatic prescribing regardless of risk and contraindications.

The POPE studies address a different problem. Diclofenac did not show benefit in reducing persistent postoperative collections or preventing late tamponade; the colchicine study did not demonstrate a significant reduction in effusion in the setting examined. These data argue against the habit of treating every collection with anti-inflammatory drugs. They do not negate the usefulness of therapy when true pericarditis is present, but they require definition of the phenotype before applying results obtained in different populations.

The tolerability of colchicine depends on organ function and interactions. Diarrhea, vomiting, and reduced food intake may complicate convalescence; more severe toxicity is possible with excessive exposure. Macrolides and other relevant inhibitors of transport or metabolic systems require caution. Advanced age and unstable renal function require individual assessment, not simple application of a weight-based dose. A preventive program should include clear criteria for reassessment or discontinuation.

Surgical strategies to promote drainage and limit collections are complementary to pharmacological prevention. Posterior pericardiotomy has been studied mainly for atrial fibrillation and pericardial accumulation in specific operations; the results are not equivalent to universal proof of prevention of the immune-mediated syndrome. Corticosteroids or other perioperative anti-inflammatory drugs likewise do not constitute indiscriminate standard prophylaxis. Effective prevention links technique, surveillance, and pharmacological selection without conflating anatomical, arrhythmic, and inflammatory outcomes.

Prognosis, complications, and functional recovery

The prognosis of the episode is often favorable, but the syndrome may prolong recovery, interrupt rehabilitation, and require readmission. Outcomes depend on the severity of inflammation, collections, and underlying heart disease. A mild form treated as an outpatient does not have the same significance as a presentation requiring drainage or involving circulatory compromise. Studies associating the syndrome with subsequent events should be interpreted considering severity and concomitant clinical factors, without automatically inferring a causal relationship.

Late tamponade is a complication that must be recognized even after discharge. New dyspnea, disproportionate fatigue, persistent tachycardia, reduced urine output, or syncope requires prompt reassessment. Localized collections may present without an evident pulsus paradoxus or without the usual global echocardiographic signs. Explaining warning symptoms is part of treatment, especially when the patient is far from the surgical center and tends to interpret every difficulty as normal convalescence.

Inflammatory recurrences may require months of treatment and a slow tapering program. A documented flare must be distinguished from chest wall pain, neuropathy, or musculoskeletal abnormalities after sternotomy. A persistent pleural effusion may also have multiple causes. Accurate definition of the problem avoids repeated corticosteroid courses without verification and allows treatment to focus on the component responsible for limitation and symptoms.

Pericardial constriction should be considered in the presence of persistent or progressive congestion not explained by other lesions. Documentation of inflammatory activity helps identify a reversible component, whereas chronic constriction requires specialist assessment and possible surgery. The risk of this complication should not be estimated from the mere presence of postoperative adhesions. An anatomical description of a thickened pericardium is not equivalent to a hemodynamic diagnosis and does not by itself constitute an indication for resection.

Clinical monitoring includes symptoms, functional capacity, physical examination, biomarkers when useful, and echocardiography according to severity and course. Follow-up is more frequent when there are significant collections, therapeutic changes, or incomplete response. Resolution of fever is not sufficient if dyspnea and congestion remain, whereas a minimal stable collection does not necessarily require prolonged therapy. The decision to taper medication should reflect overall remission and safety, not a desire to normalize every detail of the report.

Cardiac rehabilitation is adapted to control of inflammation, the wound, cardiac function, and the procedure performed. Gradual resumption avoids both premature exertion during active disease and unnecessary immobility after stabilization. A clinical letter documenting diagnosis, residual findings, therapy, and warning signs facilitates transition to the primary care physician. Coordination between cardiac surgeon and cardiologist makes it possible to verify actual recovery and promptly recognize a course requiring renewed anatomical or etiological assessment.

Bibliography
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
3. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
4. Lehto J, Kiviniemi T. Postpericardiotomy syndrome after cardiac surgery. Annals of Medicine. 2020;52(6):243-264.
5. Imazio M, Hoit BD. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. International Journal of Cardiology. 2013;168(2):648-652.
6. Sasse T, Eriksson U. Post-cardiac injury syndrome: aetiology, diagnosis, and treatment. ESC e-Journal of Cardiology Practice. 2017;15:Online scientific resource. Accessed September 26, 2026. https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-15/Post-cardiac-injury-syndrome-aetiology-diagnosis-and-treatment/.
7. Imazio M et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. European Heart Journal. 2010;31(22):2749-2754.
8. Imazio M et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016-1023.
9. Meurin P et al. Nonsteroidal anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter randomized, double-blind trial. Annals of Internal Medicine. 2010;152(3):137-143.
10. Meurin P et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomised controlled trial. Heart. 2015;101(21):1711-1716.
11. Gaudino M et al. Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. Lancet. 2021;398(10316):2075-2083.
12. U.S. National Library of Medicine. COLCHICINE tablet, film coated: prescribing information. DailyMed. n.d.. Accessed September 26, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50b9c910-49a3-4a57-80f5-dc36c09da4df.
13. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
14. Welch TD et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7(3):526-534.
15. Sagristà-Sauleda J et al. Effusive-constrictive pericarditis. New England Journal of Medicine. 2004;350(5):469-475.
16. Brucato A et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-1912.
17. Klein AL et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 2021;384(1):31-41.